Evaluating the effects of standardized hydroalcoholic extract of marmotti (Salvia mirzayanii Rech. f. & Esfand) capsule as adjunctive treatment in patient with helicobacter pylori infection

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110310006026N9

Enrollment

Registered

2019-09-23

Start date

2019-09-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

Interventions

Intervention 1: Intervention group: The treatment group receive 2 capsules of 500 mg containing bitter mulberry extract twice daily for 14 days. Intervention 2: Control group: They receive two 500 m

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patient with dyspepsia and gastrointestinal symptoms with Helicobacter pylori infection who diagnosed with stool antigen test

Exclusion criteria

Exclusion criteria: Earlier treatment of Helicobacter pylori eradication Allergic to penicillin or marmotti Stomach cancer

Design outcomes

Primary

Measure	Time frame
Stool antigen. Timepoint: The first and second weeks after the beginning of the study and 4 weeks after the end of the study. Method of measurement: Stool antigen test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Dabaghzadeh

Kerman University of Medical Sciences

fatemeh.dabaghzadeh@gmail.com+98 34 3132 5034

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026